Shopping Cart 0
Cart Subtotal
USD 0

RedHill Biopharma Ltd (RDHL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The company's commercial product portfolio consists of Donnatal for IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Release Capsules 49.3 mg for GERD and other GI conditions; and EnteraGam, a medical food intended for the dietary management. It sells these three specialty GI products in select US territories. RedHill is investigating pipeline candidates for the treatment of GI disorders and cancer that include helicobacter pylori infection, Crohn's disease, multiple sclerosis and pancreatic cancer among others. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd (RDHL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14

Partnerships 15

RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15

RedHill Biopharma Enters into Agreement with ParaPRO 16

RedHill Biopharma Enters into Research Agreement with Aarhus University 17

Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19

RedHill Biopharma Enters into Agreement with NIAID 20

RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21

Licensing Agreements 22

RedHill BioPharma Enters into Licensing Agreement with Entera Health 22

IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23

Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24

RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27

RedHill Biopharma Enters into Licensing Agreement with Temple University 28

Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30

Equity Offering 31

RedHill Biopharma Raises USD25 Million in Public Offering of American Depositary Shares 31

RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 33

RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 35

RedHill Biopharma Withdraws Public Offering of ADSs 37

RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 38

RedHill Biopharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD14.4 Million 40

RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 42

RedHill Biopharma Completes Private Placement Of Shares And Warrants For USD 11.7 Million 43

RedHill Biopharma Completes Private Placement Of Units For USD 8.5 Million 45

RedHill Biopharma Completes Private Placement Of Shares For USD 7 Million 47

RedHill Biopharma Ltd-Key Competitors 49

RedHill Biopharma Ltd-Key Employees 50

RedHill Biopharma Ltd-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 52

Financial Announcements 52

Aug 30, 2018: RedHill Biopharma reports second quarter 2018 financial results and provides update on operations 52

May 08, 2018: RedHill Biopharma Reports First Quarter 2018 Financial Results 55

Feb 22, 2018: RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update 57

Nov 13, 2017: RedHill Biopharma Reports 2017 Third Quarter Financial Results 59

Jul 25, 2017: RedHill Biopharma Reports 2017 Second Quarter Financial Results 62

May 03, 2017: RedHill Biopharma Reports 2017 First Quarter Financial Results 64

Feb 23, 2017: RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results 65

Corporate Communications 67

Jul 23, 2018: RedHill Biopharma announces uplisting to nasdaq global market 67

Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 68

Product News 69

04/19/2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D 69

01/12/2017: RedHill Biopharma Provides Milestone Update on YELIVA (ABC294640) 70

01/11/2017: RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections 71

Product Approvals 72

Sep 12, 2018: RedHill Biopharma announces positive end-of-phase II meeting with FDA on BEKINDA for IBS-D 72

Apr 04, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA for the Treatment of Cholangiocarcinoma 73

Clinical Trials 75

Sep 06, 2018: RedHill Biopharma announces advancement to second stage of phase IIa study with YELIVA for Cholangiocarcinoma 75

Sep 04, 2018: RedHill Biopharma announces completion of enrollment for confirmatory phase III study with TALICIA for H. pylori infection 76

Jul 24, 2018: RedHill Biopharma enrolls 400th patient in confirmatory phase III study with TALICIA for H. pylori Infection 77

May 30, 2018: RedHill Biopharma to Present Positive Phase II Results of BEKINDA for IBS-D at Digestive Disease Week 2018 78

May 14, 2018: RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn's Disease on May 15 79

May 07, 2018: RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn's Disease 80

May 04, 2018: RedHill Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA for H. pylori 81

Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting 82

Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D 83

Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D 84

Dec 22, 2017: RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA) for Cholangiocarcinoma at Mayo Clinic and MD Anderson 85

Nov 09, 2017: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease 86

Oct 23, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104 88

Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 89

Oct 02, 2017: RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn's Disease with Top-Line Results Expected Mid-2018 91

Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 93

Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of YELIVA in Combination Therapy for Hard-to-Treat Cancers 94

Jul 31, 2017: RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease 95

Jul 17, 2017: RedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D 97

Jul 12, 2017: RedHill Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease 98

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 100

Jun 15, 2017: RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection 101

Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 103

May 04, 2017: RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 105

Apr 24, 2017: RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D 106

Apr 20, 2017: RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA Phase I Study Results in Advanced Solid Tumors 107

Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA 109

Mar 22, 2017: RedHill Biopharma to Present at the 2017 MAP Conference 110

Mar 21, 2017: RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease 111

Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 112

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 114

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda 116

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-104 117

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-105 118

Jan 10, 2017: RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection 119

Jan 09, 2017: RedHill Biopharmas RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium 121

Jan 06, 2017: RedHill Biopharma Announces YELIVA (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference 122

Jan 04, 2017: RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium 124

Other Significant Developments 125

Apr 09, 2018: RedHill Biopharma Provides Semi-Annual Business Update 125

Dec 05, 2017: RedHill Biopharma Provides 2017 Year-End Business Update 126

Aug 10, 2017: RedHill Biopharma Provides 2017 Semi-Annual Business Update 127

Mar 29, 2017: RedHill Biopharma: Notice of Annual General Meeting of Shareholders 130

Appendix 132

Methodology 132

About GlobalData 132

Contact Us 132

Disclaimer 132


List Of Figure

List of Figures

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

RedHill Biopharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14

RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15

RedHill Biopharma Enters into Agreement with ParaPRO 16

RedHill Biopharma Enters into Research Agreement with Aarhus University 17

Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19

RedHill Biopharma Enters into Agreement with NIAID 20

RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21

RedHill BioPharma Enters into Licensing Agreement with Entera Health 22

IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23

Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24

RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27

RedHill Biopharma Enters into Licensing Agreement with Temple University 28

Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30

RedHill Biopharma Raises USD25 Million in Public Offering of American Depositary Shares 31

RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 33

RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 35

RedHill Biopharma Withdraws Public Offering of ADSs 37

RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 38

RedHill Biopharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD14.4 Million 40

RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 42

RedHill Biopharma Completes Private Placement Of Shares And Warrants For USD 11.7 Million 43

RedHill Biopharma Completes Private Placement Of Units For USD 8.5 Million 45

RedHill Biopharma Completes Private Placement Of Shares For USD 7 Million 47

RedHill Biopharma Ltd, Key Competitors 49

RedHill Biopharma Ltd, Key Employees 50

RedHill Biopharma Ltd, Subsidiaries 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

RedHill Biopharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.